X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company plans to use the net proceeds to fund its planned clinical trials for NELL-1, maintain and extend its patent portfolio, retain contract research organizations, and for working capital and other general corporate purposes.
Lead Product(s): NELL-1
Therapeutic Area: Musculoskeletal Product Name: NELL-1
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: WallachBeth Capital
Deal Size: $5.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 12, 2022
Details:
Bone Biologics has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.
Lead Product(s): rhNELL-1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
